Deuterium-and tritium-labeled pharmaceutical compounds are pivotal diagnostic tools in drug discovery research, providing vital information about the biological fate of drugs and drug metabolites. Herein we demonstrate that a photoredox-mediated hydrogen atom transfer protocol can efficiently and selectively install deuterium (D) and tritium (T) at a-amino sp 3 carbon-hydrogen bonds in a single step, using isotopically labeled water (D 2 O or T 2 O) as the source of hydrogen isotope. In this context, we also report a convenient synthesis of T 2 O from T 2 , providing access to high-specific-activity T 2 O. This protocol has been successfully applied to the high incorporation of deuterium and tritium in 18 drug molecules, which meet the requirements for use in ligand-binding assays and absorption, distribution, metabolism, and excretion studies.
A n essential component of the drug discovery and development process is the thorough elucidation of a drug molecule's action and toxicity (1) (2) (3) (4) (5) (6) (7) (8) (9) . Despite rapid advancements in analytical techniques over the past 20 years, the introduction of isotopic labels, which integrates a distinguishing signal into a molecule without drastically altering its function, remains the most effective method to detect and quantify drugs and drug metabolites both in vivo and in vitro (1) (2) (3) (4) (5) (6) . Recently, the ability to introduce hydrogen isotopes at nonlabile C-H moieties has led to the emergence of deuterium ( 2 H, D) and tritium ( 3 H, T) as cheaper and more readily accessible alternatives to 13 C and 14 C for the synthesis of isotopically labeled drug analogs, especially when high isotopic incorporation is desired (1) (2) (3) (4) (5) (6) . In particular, highly deuterated analogs of drug molecules are used in absorption, distribution, metabolism, and excretion (ADME) studies, where they are ideal internal standards for mass spectrometry-based quantification in animal and human samples, because they negate matrix effects that can interfere with accurate quantification (10, 11) . Highspecific-activity tritium analogs are critical for accurate quantification in nanomolar ligandbinding affinity studies, as well as the imaging of in vivo compound distribution by autoradiography (7) (8) (9) .
A large majority of deuterium-and tritiumlabeled pharmaceutical compounds are synthesized in multistep procedures involving the reduction of halogenated or unsaturated drug precursors (1) (2) (3) (4) (5) (6) . However, advances in transition metal-catalyzed C-H activation have allowed for direct hydrogen isotope exchange (HIE) at C-H bonds for deuterium or tritium, enabling the synthesis of labeled compounds in a single step without the need for resynthesis (12) (13) (14) . This straightforward approach has recently found widespread application in the pharmaceutical industry, where the increasing impact of earlystage ligand-binding assays and ADME studies on drug discovery has led to a rising demand for the efficient synthesis of isotopically labeled pharmaceutical compounds (2) .
Transition metal-catalyzed HIE reactions at aromatic C(sp 2 )-H moieties are well established (Fig. 1A) . For example, cationic iridium(I) complexes have long been used to selectively label sites ortho to directing groups on aromatic rings (12, 13) . More recently, Chirik and co-workers reported the use of an iron catalyst for the deuteration and tritiation of pharmaceutical drugs at aromatic C-H moieties without the need for a directing group, enabling orthogonal site selectivity relative to the iridium catalyst (14) . In contrast, the direct HIE at aliphatic C(sp 3 )-H moieties remains a challenge in the field (15) (16) (17) (18) (19) (20) . With more than 50% of the top-selling commercial drugs containing at least one alkyl amine moiety (21) , the development of a HIE reaction targeting a-amino C(sp 3 )-H bonds could potentially provide a general method for the isotopic labeling of the aliphatic positions of a drug molecule. The site of the isotopic label can be of vital importance, depending on the nature of the study and the metabolic pathways of the substrate of interest (1) (2) (3) (4) (5) (6) . In addition, the inherently larger number of exchangeable hydrogens at a-amino C-H moieties relative to aromatic C-H moieties enables high incorporation of the desired isotopic label, which is often necessary for the labeled compound to be of practical use in pharmaceutical studies. Therefore, the development of a mild and efficient HIE reaction targeting a-amino C(sp 3 )-H bonds is particularly attractive for the pharmaceutical industry.
Visible light-mediated photoredox catalysis has emerged in recent years as an enabling platform to access new organic transformations through single-electron transfer events (22) (23) (24) . In particular, our laboratory and others have demonstrated that tertiary amines can be activated by singleelectron oxidation to give an amine radical cation, which can undergo facile a-deprotonation to yield carbon-centered a-amino radicals. The synthetic utility of a-amino radicals has been showcased by its ability to couple with various electrophilic partners (25) (26) (27) . On this basis, we questioned whether we could exploit a-amino radicals to access a-deuterated or a-tritiated products (Fig.  1B) . Specifically, we hypothesized that, instead of trapping the a-amino radical with a carbon electrophile, the use of an appropriate hydrogen atom transfer (HAT) catalyst in equilibrium with D 2 O or T 2 O could facilitate the abstraction of deuterium or tritium to yield labeled products. We recognized that the choice of the HAT catalyst would be heavily influenced by thermodynamic factors, particularly the bond dissociation energy (BDE) relative to that of the a-amino C-H bond, as well as its pK a (where K a is the acid dissociation constant) relative to water (Fig. 1B) (28) (29) (30) . With these considerations in mind, we postulated that thiols, which have been demonstrated to be good hydrogen atom donors (31), would be suitable HAT catalysts for this transformation. Herein we describe direct HIE at a-amino C(sp 3 )-H bonds mediated by the synergistic merger of photoredox and HAT catalysis. This methodology was readily applied to the program-scale deuteration (32) and high-specific-activity tritiation of 18 representative drugs and drug candidates.
A proposed mechanism for the photoredox-and HAT-catalyzed HIE of a-amino C(sp 3 )-H bonds is shown in Fig. 2A (33) . Initial photoexcitation of the iridium(III) photocatalyst Ir(F-Meppy) 2 (dtbbpy)PF 6 (34) and can oxidize amine 3, which undergoes facile deprotonation at the a-position to give a-amino radical 4. At the same time, a thiol HAT catalyst (6) would undergo exchange with T 2 O to give the tritiated thiol 7, which would serve as the source of tritium. In addition to the reported BDE for typical a-amino C-H and thiol S-H bonds, we reasoned that HAT can proceed between the polarity-matched (35) nucleophilic a-amino radical 4 and tritiated thiol 7, which would furnish a-tritiated amine product 8 and the electrophilic thiol radical 9 [a-amino C-H BDE = 93.0 kcal mol We began our investigations into the proposed isotopic-labeling protocol by first examining the deuteration of clomipramine (11) hydrochloride (Anafranil), a commercially available antidepressant. For the application of deuterated compounds as internal standards in pharmaceutical studies, each compound should ideally have an isotopic incorporation of more than 4.0 deuteriums per molecule, with less than 0.1% of the unlabeled compound remaining, so as to avoid peak overlaps on the mass spectrum and allow for accurate quantification (11) . In addition, to facilitate long-term studies, the programscale synthesis of a uniformly deuterated batch of compound is also highly desirable (Fig. 2B,  left) . A variety of photoredox and thiol catalysts and their respective loadings were evaluated, using N-methyl-2-pyrrolidone (NMP) as the solvent (figs. S1 and S2). In our preliminary studies conducted at a 0.1-mmol scale, we observed that the use of 2 mol % of organic photocatalyst 4Cz-IPN (12) (Fig.  2B, left) . The use of the sterically hindered triisopropylsilanethiol was critical to prevent a deleterious thiol-substrate coupling pathway ( fig. S2) . Control experiments also revealed that light, photoredox catalyst, and thiol are all essential for deuteration to proceed (table S1) .
Next, we sought to extend this HIE protocol to the high-specific-activity tritiation of aminecontaining drugs with T 2 O. In contrast to the deuterium HIE reactions, the analogous tritium HIE reactions are predominantly run on a micromolar scale because (i) the tritium isotope is easily detectable and only a small amount of radioactive product is required, and (ii) safety and cost concerns favor limiting the amount of tritium used to 1.0 Ci (17.2 mmol) per reaction. An additional complication is that commercially available T 2 O is typically highly diluted with naturalabundance H 2 O to prevent the decomposition of T 2 O through autoradiolysis (Fig. 2C) (3) . To overcome this issue, we set out to establish a convenient process to synthesize high-specificactivity T 2 O using only 1 Ci of T 2 gas, which could be performed in a common laboratory setting and used immediately in our tritium HIE reaction. Industrially, neat T 2 O is produced in bulk from the reaction between T 2 and PtO 2 before being distilled and diluted (40) . To facilitate the transfer of micromolar-scale T 2 O into our photoredox reaction mixture, we proposed to adapt this procedure for the generation of T 2 O in a potential reaction solvent. Among the solvents evaluated, we observed that the use of NMP as the reaction solvent enabled the formation of highspecific-activity tritiated water in 61% yield (0.51 Ci, 8.8 mmol) from 1.0 Ci T 2 gas and PtO 2 ( fig. S3 ).
With this convenient method to access T 2 O in hand, we proceeded to optimize the proposed photoredox-HAT-catalyzed tritium-labeling protocol. In general, high-specific-activity tritium-labeled compounds are required to have a specific activity of at least 15 Ci mmol −1 (equivalent to an incorporation of 0.5 tritiums per molecule) and are isolated in an appreciable radiochemical yield of at least 10 mCi (Fig. 2B, right) . Under the dilute micromolar conditions (using~4.4 equivalents of T 2 O), we observed that the use of 11 in its free base form-along with increased loadings of the photoredox (4 mol %) and thiol (60 mol %) catalystsand the use of the integrated photoreactor developed at Merck & Co., Inc. (41) (Fig. 2B, right) .
Under these optimized conditions, we explored the generality of the photoredox-mediated deuteration and tritiation protocols with a library of commercially available drugs containing a variety of alkyl amine scaffolds. For the deuteration of these substrates (Fig. 3) , the best conditions were found to be substrate-dependent, given a choice of two photocatalysts [Ir(F-Meppy) 2 (dtbbpy)PF 6 (1) and 4Cz-IPN (12) With the same library of 13 pharmaceutical drugs, we demonstrated similar functional group tolerance for the photoredox-mediated tritium HIE protocol (Fig. 4) . As with the deuteration reaction, the best conditions were substrate-dependent, and combinations of the two photocatalysts 1 and 12 and the two thiols triisopropylsilanethiol (13) and methyl thioglycolate (14) were used. Despite the smaller excess of T 2 O in the reaction, the presence of acidic hydrogens from carbamate ([ that are labeled and the percent incorporation of the hydrogen isotope, respectively. NMP, N-methyl-2-pyrrolidone; t-Bu, tert-butyl group; rt, room temperature; h, hours. (C) High-specific-activity T 2 O is accessible from T 2 and PtO 2 at a micromolar scale and can be used for photoredoxcatalyzed tritiation in a one-pot procedure.
these substrates have no aromatic rings and cannot be tritiated using existing HIE protocols. For [ 3 H]22, when the amount of T 2 gas was increased to 2 Ci, specific activity was boosted from 11.5 to 14.6 Ci mmol −1 , with a large increase in yield (8.6 to 19.6 mCi). This demonstrates the tunability of our protocol with respect to the amount of T 2 used, enabling single-step tritiation even for particularly recalcitrant substrates. We achieved high specific activities for all substrates, meeting the typical standards for the preparation of high-specific-activity pharmaceutical drugs in appreciable yield for use in ligand-binding studies.
In addition to the library of commercially available drug molecules, we further evaluated the utility of this photoredox-catalyzed tritiation with a series of potential GPR-40 agonists with positive allosteric modulation (agoPAMs) (Fig. 4) developed in the research laboratories of Merck & Co., Inc. (43) . The characterization of G proteincoupled receptor allostery is critical to advancing this agoPAM chemical class. Augmentation of binding in the presence of orthosteric ligands has been previously demonstrated using radiolabeled analogs in radioligand-binding assays and subsequently visualized in the GPR-40 ternary crystal structure (44) . As such, we envision that the radiolabeling methodology described herein might be used to enable metabolite identification both in vitro and in vivo, as well as the elucidation of the extent of covalent protein binding in human hepatocytes to lower the risk of any bioactivation toward reactive electrophiles (45) .
Initially, we observed photoredox-mediated decarboxylation of the aliphatic carboxylic acid moiety in the drug candidates. However, this was overcome by using a less oxidizing photocatalyst, Ir(ppy) 2 met the requirements for use in preclinical candidate selection studies. We anticipate that facile access to highly deuterated and tritiated compounds based on the method described herein will enable accelerated and broader interrogation of the biological activity of molecules in the pursuit of the development of new molecular therapies. 
